Abstract
Hypoxia is a well-recognized feature of human solid tumors. It is also well recognized, by both physicians and investigators, that malignant disease in various organs/tissues in the same patient, or the same tumor cells implanted in different sites or organs in the preclinical host, have different levels of hypoxia and different levels of response to systemic therapies. Over the past 10 years, it has been established that normal cells involved in the malignant disease process can be important targets for therapeutic attack. A prime example of ‘normal’ cells that have come to the fore as anticancer therapeutic targets is endothelial cells.
The field of antiangiogenic therapies was fueled by the early hypothesis which held that angiogenesis was the same no matter where it occurred. The corollary to this hypothesis was that models of normal embryo development, as well as models working with mature well-differentiated endothelial cells in culture, would be sufficient and satisfactory models for tumor endothelial cells. However, the current hypothesis is that angiogenesis occurring during malignant disease is abnormal, and that therapeutic targets identified by studying endothelial cells isolated from fresh samples of human cancers will be most relevant in developing therapeutic agents to treat human malignant disease.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
4. References
C. M. Doll, M. Milosevic, M. Pintilie, R. P. Hill, and A. W. Fyles, Estimating hypoxic status in human tumors: A simulation using Eppendorf oxygen probe data in cervical cancer patients, Int. J. Radiat. Oncol. Biol. Phys. 55(5), 1239–1246 (2003).
A. Fyles, M. Milosevic, D. Hedley, M. Pintilie, W. Levin, L. Manchul, and R. P. Hill, Tumor hypoxia has independent predictor impact only in patients with node-negative cervix cancer, J. Clin. Oncol. 20(3), 680–687 (2002).
J.-Y. Wang, K.-Y. Chen, J.-T. Wang, J.-H. Chen, J.-W. Lin, H.-C. Wang, L.-N. Lee, and P.-C. Yang, Outcome and prognostic factors for patients with non-small cell lung cancer and severe radiation pneumonitis, Int. J. Radiat. Oncol. Biol. Phys. 54(3), 735–741 (2002).
J. Dunst, T. Kuhnt, H. G. Strauss, U. Krause, T. Pelz, H. Koelbl, and G. Haensgen, Anemia in cervical cancers: impact on survival, patterns of relapse, and association with hypoxia and angiogenesis, Int. J. Radiat. Oncol. Biol. Phys. 56(3), 778–787 (2003).
B. Movsas, J. D. Chapman, A. L. Hanlon, E. M. Horwitz, W. H. Pinover, R. E. Greenberg, C. Stobbe, and G. E. Hanks, Hypoxia in human prostate carcinoma: An Eppendorf PO2 study, Am. J. Clin. Oncol. 24(5), 458–461 (2001).
P. Subarsky, and R. P. Hill, The hypoxic tumor microenvironment and metastatic progression, Clin. Exp. Metastasis 20, 237–250 (2003).
S. A. Holden, Y. Emi, Y. Kakeji, D. Northey, and B. A. Teicher, Host distribution and response to antitumor alkylating agents of EMT-6 tumor cells from subcutaneous tumor implants, Cancer Chemother. Pharmacol. 40, 87–93 (1997).
B. A. Teicher, G. Ara, S. R. Keyes, R. S. Herbst, and E. Frei III, Acute in vivo resistance in high-dose therapy, Clin. Cancer Res. 4, 483–491 (1998).
B. St. Croix, C. Rago, V. Velculescu, G. Traverso, K. E. Romans, E. Montgomery, A. Lai, G. J. Riggins, C. Lengauer, B. Vogelstein, and K. W. Kinzler, Genes expressed in human tumor endothelium, Science 289(5482), 1197–1202 (2000).
R. G. Bagley, J. Walter-Yohrling, X. Cao, W. Weber, B. Simons, B. P. Cook, S. D. Chartrand, C. Wang, S. L. Madden, and B. A. Teicher, Endothelial precursor cells as a model of tumor endothelium: characterization and comparison with mature endothelial cells, Cancer Res. 63(18), 5866–5873 (2003).
Y. Kakeji, and B. A. Teicher, Preclinical studies of the combination of angiogenic inhibitors with cytotoxic agents, Invest. New Drugs 15, 39–48 (1997).
K. A. Keyes, L. Mann, K. Cox, P. Treadway, P. Iversen, Y.-F. Chen, and B. A. Teicher, Circulating angiogenic growth factor levels in mice bearing human tumors using Luminex multiplex technology, Cancer Chemother. Pharmacol. 51, 321–327 (2003).
K. Keyes, K. Cox, P. Treadway, L. Mann, C. Shih, M. M. Faul, and B. A. Teicher, An in vitro tumor model: analysis of angiogenic factor expression after chemotherapy, Cancer Res. 62, 5597–5602 (2002).
B. A. Teicher, K. Menon, E. Alvarez, E. Galbreath, C. Shih, and M. M. Faul, Antiangiogenic and antitumor effects of a protein Kinase Cb inhibitor in human T98G glioblastoma multiforme xenografts, Clin. Cancer Res. 7, 634–640 (2001).
K. A. Keyes, L. Mann, M. Sherman, E. Galbreath, L. Schirtzinger, D. Ballard, Y.-F. Chen, P. Iversen, and B. A. Teicher, LY317615 decreases plasma VEGF levels in human tumor xenograft bearing mice, Cancer Chemother. Pharmacol. 53(2), 133–140(2003).
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2005 Springer Science+Business Media, Inc.
About this paper
Cite this paper
Teicher, B.A. (2005). Hypoxia, Tumor Endothelium, and Targets for Therapy. In: Okunieff, P., Williams, J., Chen, Y. (eds) Oxygen Transport to Tissue XXVI. Advances in Experimental Medicine and Biology, vol 566. Springer, Boston, MA. https://doi.org/10.1007/0-387-26206-7_5
Download citation
DOI: https://doi.org/10.1007/0-387-26206-7_5
Publisher Name: Springer, Boston, MA
Print ISBN: 978-0-387-25062-5
Online ISBN: 978-0-387-26206-2
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)